An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy

Archives of Ophthalmology
C S YangG J Jaffe

Abstract

To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR). The therapeutic efficacy of the TA/5-FU codrug was determined in a rabbit model that simulates human PVR. Intravitreal levels of triamcinolone and 5-fluorouracil were measured at different time points and drug release in vitro was tested. Toxic effects were evaluatedby electroretinograpy, clinical examination, and light microscopy. Both the severity of PVR grade and the percentage of eyes with moderate or worse tractional detachment were significantly less in eyes treated with the codrug. The therapeutic effect of the intravitreal codrug was paralleled by sustained intravitreal levels of triamcinolone and 5-fluorouracil. There were no drug-related toxic effects evident on clinical or histopathologic examination of eyes containing the TA/5-FU codrug. The intravitreal sustained-release TA/5-FU codrug effectively inhibits the progression of PVR in a rabbit model that closely resembles PVR in humans. The TA/5-FU codrug may simultaneously target different components of the wound-healing response.

Citations

Nov 18, 2006·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Tamer A MackyNihal El Shazly
Jul 12, 2014·Journal français d'ophtalmologie·C Chiquet, F Rouberol
Oct 27, 1999·The British Journal of Ophthalmology·G Velez, S M Whitcup
Jun 6, 2000·The British Journal of Ophthalmology·C S SethiN H Chong
Dec 19, 2002·The British Journal of Ophthalmology·J B JonasR Degenring
Mar 19, 2003·The British Journal of Ophthalmology·J B JonasR Degenring
Aug 26, 1999·International Journal of Pharmaceutics·S EinmahlR Gurny
Apr 3, 2012·Journal of Materials Science. Materials in Medicine·Flávia Carmo Horta PintoGisele Rodrigues Da Silva
Sep 28, 2007·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·K H EiblA Kampik
Jul 26, 2015·Progress in Retinal and Eye Research·J Carlos PastorSantiago Delgado-Tirado
Mar 2, 2006·Expert Opinion on Drug Delivery·Tsutomu YasukawaYasuhiko Tabata
Mar 11, 2005·Expert Opinion on Emerging Drugs·Grant M ComerMark H Criswell
Aug 9, 2007·Expert Opinion on Drug Delivery·Kumar G JanoriaAshim K Mitra
Nov 7, 2009·Journal of Pharmaceutical Sciences·Yahya E ChoonaraLisa C du Toit
Oct 5, 2010·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·N DasS K Shrivastava
Jun 12, 2010·Experimental Eye Research·Xin LiuEun-Kee Jeong
Mar 25, 2008·Optometry : Journal of the American Optometric Association·Tilena WatersJoseph Sowka
Apr 1, 2005·Acta Ophthalmologica Scandinavica·Caroline Schmidt LaugesenMorten la Cour
Jun 5, 2004·Progress in Retinal and Eye Research·Tsutomu YasukawaYoshihito Honda
Nov 17, 2006·Advanced Drug Delivery Reviews·J L BourgesF Behar-Cohen
Oct 14, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·M Naveed YasinIlva D Rupenthal
May 1, 2004·Current Opinion in Ophthalmology·Thomas A CiullaMark H Criswell
Mar 8, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hsi-Kung KuoDan-Ning Hu
Apr 11, 2000·Journal of Biomedical Materials Research·S EinmahlR Gurny
Nov 16, 2005·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Chang-Sue YangWen-Ming Hsu
Mar 29, 2001·Clinical & Experimental Ophthalmology·S YoungS Lightman
May 22, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jae Pil ShinSi Yeol Kim
Aug 25, 2005·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ortrud UckermannSusann Uhlmann
Feb 3, 2009·Pharmaceutical Research·Saffar MansoorM Cristina Kenney
Jan 29, 2010·Drugs & Aging·Noriyuki Kuno, Shinobu Fujii
Nov 2, 2018·The British Journal of Ophthalmology·Nikolas J S LondonCarl D Regillo
Dec 5, 2014·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·Ali M Al-Halafi
Feb 8, 2007·Drugs·Lekha M AbrahamIgal Leibovitch
May 9, 2001·Clinical & Experimental Ophthalmology·S Lightman
Mar 11, 2000·Biomaterials·M J ColthurstI Grierson

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.